“…It also interacts with transcription factors or co-factors, including p53, FOXO family member, NF-κB, myoblast determination protein 1, nuclear receptor corepressor, p300 and peroxisome proliferator-activated receptor γ coactivator 1-α, and regulates their transcriptional activity. SIRT1 inhibitors exhibit antitumor activity, which has been observed in cells from breast, thyroid, lung, pancreatic, prostate, hepatitis and colon cancer (17)(18)(19)(20)(21). Moreover, SIRT1 has effective antitumor activity against hematological malignancies, such as T/B-cell lymphoma, chronic myeloid leukemia (CML), leukemia and other hematological malignancies (11,(22)(23)(24)(25)(26).…”